This follows from earlier studies identifying genetic mutations that are rare in the general population and predict risk of Mendelian (sub-types of) diseases with high sensitivity and specificity (for example BRCA1/2 in familial breast and ovarian cancer). This evidence concerns the gene BRCA1 and ovarian carcinoma.